The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.20 - Manufacture of pharmaceutical preparations
150 jobs Number of planned job creations
Announcement Date
19 March 2013
Employment effect (start)
Foreseen end date
31 December 2013
Description
PrimeCell, a global company working in the field of regenerative medicine, is to set up an international centre in Ostrava and to create 150 new jobs by the end of 2013. With the help of European subsidies, the centre 4MEDi-Biotech Park for Medical Innovations will develop products from human cells for the treatment of inadequately treated or incurable diseases such as multiple sclerosis, Alzheimer's disease or diabetes. The investment of the project amounted to a total of CZK 702 million.
Sources
19 March 2013: CzechInvest
Citation
Eurofound (2013), PrimeCell, Business expansion in Czechia, factsheet number 75101, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/75101.